Long-term B-Lymphocyte Depletion With Rituximab in Patients With Relapsing-Remitting Multiple Sclerosis

被引：35

作者：

Stuve, Olaf ^{[2
,3
]}

Leussink, Verena I. ^{[1
]}

Froehlich, Ruth ^{[1
]}

Hemmer, Bernhard ^{[4
]}

Hartung, Hans-Peter ^{[1
]}

Menge, Til ^{[1
]}

Kieseier, Bernd C. ^{[1
]}

机构：

[1] Univ Dusseldorf, Dept Neurol, D-40225 Dusseldorf, Germany

[2] Univ Texas SW Med Ctr Dallas, Div Neurol, Med Serv, Dallas Vet Affairs Med Ctr, Dallas, TX 75390 USA

[3] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA

[4] Tech Univ Munich, Klinikum Rechts Isar, Dept Neurol, D-8000 Munich, Germany

来源：

ARCHIVES OF NEUROLOGY | 2009年 / 66卷 / 02期

关键词：

PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; CEREBROSPINAL-FLUID; CELL;

D O I：

10.1001/archneurol.2008.551

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Objective: To describe 2 patients with relapsing-remitting multiple sclerosis (RRMS) receiving longterm treatment with the monoclonal antibody rituximab. The clinical and paraclinical efficacy of rituximab was demonstrated recently in a phase 2 clinical trial in patients with RRMS. Design: Case series. Setting: Tertiary care university medical center. Patients: Two young patients with highly active RRMS in whom standard therapy had failed before receiving rituximab for up to 48 months. Main Outcome Measures: Relapse rate, clinical disability, and results of magnetic resonance imaging. Results: Both patients tolerated rituximab treatment well and have been clinically stable throughout the study period. Conclusion: Long-term therapy with rituximab appears safe and effective in some patients with RRMS. Our observation should be confirmed in controlled long-term trials.

引用

页码：259 / 261

页数：3

共 50 条

[1] B-cell depletion with Rituximab in relapsing-remitting multiple sclerosis
Hauser, Stephen L.
Waubant, Emmanuelle
Arnold, Douglas L.
Vollmer, Timothy
Antel, Jack
Fox, Robert J.
Bar-Or, Amit
Panzara, Michael
Sarkar, Neena
Agarwal, Sunil
Langer-Gould, Annette
Smith, Craig H.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (07): : 676 - 688
[2] B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Dennis Bourdette
Vijayshree Yadav
[J]. Current Neurology and Neuroscience Reports, 2008, 8 (5) : 417 - 418
[3] Role of B Cells in Relapsing-Remitting and Progressive Multiple Sclerosis and Long-Term Effects of B Cell Depletion
Shirani, Afsaneh
Stuve, Olaf
Cross, Anne H.
[J]. NEUROLOGIC CLINICS, 2024, 42 (01) : 137 - 153
[4] Rituximab for relapsing-remitting multiple sclerosis
He, Dian
Guo, Rui
Zhang, Fubo
Zhang, Chao
Dong, Shuai
Zhou, Hongyu
[J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (12):
[5] Rituximab in relapsing-remitting multiple sclerosis
Schrijver, Hans M.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (24): : 2645 - 2645
[6] Rituximab for relapsing-remitting multiple sclerosis
He, Dian
Zhou, Hongyu
Han, Wenjie
Zhang, Shihong
[J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2011, (12):
[7] Long-term outcome of minocycline in relapsing-remitting multiple sclerosis
Zhang, Y.
Metz, L. M.
Yong, V. W.
Bell, R. B.
Yeung, M.
Patry, D.
Mitchel, J. R.
[J]. MULTIPLE SCLEROSIS, 2007, 13 (09): : 1226 - 1226
[8] Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis
Stüve, O
Cepok, S
Elias, B
Saleh, A
Hartung, HP
Hemmer, B
Kieseier, BC
[J]. ARCHIVES OF NEUROLOGY, 2005, 62 (10) : 1620 - 1623
[9] Long-term adherence to interferon β therapy in relapsing-remitting multiple sclerosis
Portaccio, E.
Zipoli, V.
Siracusa, G.
Sorbi, S.
Amato, M. P.
[J]. EUROPEAN NEUROLOGY, 2008, 59 (3-4) : 131 - 135
[10] Relapsing-remitting multiple sclerosis: a long-term observation of immunomodulatory therapy
Romanowski, F
Straube, E
Heinemann, J
Rhein, R
[J]. JOURNAL OF NEUROLOGY, 2004, 251 : 152 - 152

← 1 2 3 4 5 →